Mosunetuzumab Clinical Trials
26 recruitingDrug
Phase 219Phase 18Phase 32
Showing 1–20 of 26 trials
Recruiting
Phase 3
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features
National Cancer Institute (NCI)600 enrolled261 locationsNCT06337318
Recruiting
Phase 1
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
National Cancer Institute (NCI)30 enrolled8 locationsNCT06015880
Recruiting
Phase 1Phase 2
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
OHSU Knight Cancer Institute30 enrolled1 locationNCT06249191
Recruiting
Phase 1
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Washington University School of Medicine15 enrolled1 locationNCT05412290
Recruiting
Phase 2
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Recurrent Follicular LymphomaRefractory Follicular LymphomaGrade 1 Follicular Lymphoma+2 more
University of Washington22 enrolled1 locationNCT06948786
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1Phase 2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb308 enrolled65 locationsNCT06090539
Recruiting
Phase 2
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Nodular Lymphocyte Predominant B-Cell LymphomaRecurrent Nodular Lymphocyte Predominant B-Cell LymphomaRefractory Nodular Lymphocyte Predominant B-Cell Lymphoma
National Cancer Institute (NCI)70 enrolled35 locationsNCT05886036
Recruiting
Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Hoffmann-La Roche137 enrolled31 locationsNCT05091424
Recruiting
Phase 2
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Hodgkin Lymphoma
M.D. Anderson Cancer Center36 enrolled1 locationNCT05615636
Recruiting
Phase 1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
ADC Therapeutics S.A.200 enrolled42 locationsNCT04970901
Recruiting
Phase 2
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular Lymphoma+6 more
University of Washington20 enrolled1 locationNCT06442475
Recruiting
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
Relapsed/Refractory Follicular Lymphoma
Andrés José Maria Ferreri25 enrolled1 locationNCT07278921
Recruiting
Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network396 enrolled87 locationsNCT05633615
Recruiting
Phase 2
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Lymphoma
M.D. Anderson Cancer Center36 enrolled1 locationNCT06563505
Recruiting
Phase 2
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
LymphomaFollicular Lymphoma
Memorial Sloan Kettering Cancer Center152 enrolled9 locationsNCT05389293
Recruiting
Phase 2
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Refractory Non-Hodgkin LymphomaRelapsed Non Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma
Lazaros Lekakis22 enrolled1 locationNCT05260957
Recruiting
Phase 2
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Follicular LymphomaMarginal Zone LymphomaB-cell Lymphoma
Brown University52 enrolled3 locationsNCT04792502
Recruiting
Phase 1Phase 2
Mosunetuzumab for CLL MRD Clearance
Chronic Lymphocytic LeukemiaLymphomaLeukemia+1 more
Inhye Ahn40 enrolled2 locationsNCT07052695
Recruiting
Phase 2
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
Extranodal Marginal Zone Lymphoma
Izidore Lossos, MD35 enrolled1 locationNCT06569680